SS-31
Elamipretide (Szeto-Schiller Peptide 31)
At a Glance
Molecular Properties
Overview
Compound Description
SS-31, also designated elamipretide and MTP-131, is a synthetic aromatic-cationic tetrapeptide belonging to the Szeto-Schiller (SS) family of mitochondria-targeting compounds. Its defining structural feature is an alternating arrangement of basic and aromatic residues that is reported in the literature to concentrate the peptide at the inner mitochondrial membrane. This profile is provided for research and educational purposes only and does not describe any approved or intended use in humans. SS-31 is studied as a laboratory reference compound in preclinical mitochondrial biology.
Mechanism of Action
Research-Identified Pathways
Published research indicates that SS-31 associates selectively with cardiolipin, an anionic phospholipid that is largely restricted to the inner mitochondrial membrane. Biophysical studies report that the peptide partitions into the membrane interfacial region through combined electrostatic and hydrophobic interactions and modulates the surface electrostatics and lipid packing of model and mitochondrial membranes. Through this cardiolipin interaction, research models describe SS-31 as helping to preserve the organization of the electron transport chain and the architecture of mitochondrial cristae.
In preclinical systems, research indicates that this cardiolipin binding is associated with maintenance of cytochrome c electron-carrier function and with reduced generation of reactive oxygen species under conditions of mitochondrial stress. Reported observations in cell and animal models include effects on oxidative phosphorylation efficiency and cristae network stability. These mechanistic descriptions derive from laboratory and animal studies and are not statements of clinical efficacy or human benefit.
Key Research Findings
Published Study Highlights
- Biophysical studies report that SS-31 partitions into lipid bilayers and modulates membrane surface electrostatics in a manner related to membrane surface charge (Mitchell et al., 2020).
- Cross-linking mass spectrometry has been used to map an SS-31 mitochondrial protein interaction landscape, associating the peptide with components of oxidative phosphorylation and 2-oxoglutarate metabolism (Chavez et al., 2020).
- Research characterizes SS-31 as a cardiolipin-interacting compound proposed to protect cardiolipin's role in electron transport chain organization in preclinical models (Szeto, 2014).
- In a rat cardiac ischemia-reperfusion model, the cardiolipin-binding peptide was reported to mitigate fragmentation of mitochondrial cristae networks (Allen et al., 2020).
- Review literature summarizes preclinical observations of reduced reactive oxygen species generation and stabilized cristae structure across multiple mitochondrial-stress models (Tung et al., 2025).
Areas of Research Interest
Why Researchers Are Investigating This Compound
This compound has attracted significant research attention in the following areas. These represent active fields of scientific inquiry, not validated therapeutic claims. No medical benefits are stated or implied.
- Mitochondrial dysfunction research: used as a cardiolipin-targeting tool compound to probe inner-membrane organization and bioenergetic behavior in cell and tissue models; not a validated benefit.
- Ischemia-reperfusion models: investigated in preclinical cardiac and organ ischemia-reperfusion systems for effects on cristae architecture and mitochondrial reactive oxygen species; outcomes are experimental only.
- Age-related mitochondrial research: examined in aging-model systems for associations with oxidative phosphorylation efficiency and reactive oxygen species production; findings are preclinical and not clinical claims.
- Structure-activity and membrane-interaction research: studied to understand how the alternating cationic-aromatic motif governs cardiolipin binding and membrane surface electrostatics; strictly mechanistic laboratory interest.
Published Research
Peer-Reviewed References
- Szeto HH, et al. "First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics." British Journal of Pharmacology (2014). doi:10.1111/bph.12461
- Mitchell W, et al. "The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action." Journal of Biological Chemistry (2020). doi:10.1074/jbc.RA119.012094
- Chavez JD, et al. "Mitochondrial protein interaction landscape of SS-31." Proceedings of the National Academy of Sciences (2020). doi:10.1073/pnas.2002250117
- Allen ME, et al. "The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats." Communications Biology (2020). doi:10.1038/s42003-020-1101-3
- Tung C, et al. "Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential." International Journal of Molecular Sciences (2025). doi:10.3390/ijms26030944
Research Use Only
The information presented on this page is compiled from peer-reviewed scientific literature and is provided solely for educational and research purposes. This compound is intended exclusively for laboratory and scientific research use. It is not a drug, pharmaceutical, or dietary supplement. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition. No claims of therapeutic efficacy are made or implied.
Researchers are advised to consult the original published studies referenced above for complete methodological details, study limitations, and the authors' own conclusions. Atlas Peptide Research does not endorse any specific research application and provides this information as a reference resource only.
Interested in SS-31?
View this compound in our shop to see available sizes, certificates of analysis, and current pricing.
View in Shop